© Florida Institue for Clinical Research | Privacy Policy
Website by 
COPD (THARROS)
AstraZeneca D5989C00001
A Study Evaluating the Efficacy of Breztri/Trixeo on Cardiopulmonary Outcomesin patients with Chronic Obstructive Pulmonary Disease. This study seeks to demonstrate that the use of triple therapy (Breztri/Trixeo) will improve cardiopulmonary outcomes as well as reduce exacerbations in a population with COPD and high cardiopulmonary risk.
To Participate in the study you must:
- Be 40 to 80 years of age
- Have a diagnosis of COPD confirmed by a post-bronchodilator FEV1/FVC < 70%
- Be a current or former smoker with a history of at least 10 pack-years of cigarette smoking
- Have a history of cardiovascular disease or risk factors (ie. angina, myocardial infarction, ischemic stroke, peripheral arterial disease, hypertension, diabetes mellitus, hypercholesterolemia, and obesity)